VRTX

Mark E. Bunnage

Known title: EVP, Chief Scientific OfficerCIK: 0002100735

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 17, 2026

Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.

this person other insiders at VRTX

Transaction History

VRTX▼ Sell$15K
VRTX▼ Sell$302K
VRTX▼ Sell$282K
VRTX▼ Sell$560K
VRTX▼ Sell$537K
VRTX▼ Sell$1.2M
VRTX▲ Buy$0
VRTX▼ Sell$1.1M
VRTX▼ Sell$931K
VRTX▼ Sell$528K

We use analytics to understand how market-wall is used. No personal data is sold.